Biopharma sales slightly lower than expected at Novo Nordisk

While Novo Nordisk increased its biopharma sales in 2021 compared to 2020, the Danish pharmaceutical giant did not manage to beat the estimations made by analysts.

Photo: Novo Nordisk / PR

Novo Nordisk’s biopharma arm saw sales grow to DKK 4.7bn (USD 713.9m) in the fourth quarter of 2021, up from DKK 4.4bn (USD 668.35m) the same period last year, according to Novo’s financial figures, which were released on Wednesday.

According to estimates collected by the company itself prior to the report, analysts had predicted that Novo’s biopharma sales would amount to DKK 4.8bn (USD 729.1m).

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs